Regeneronreason 01 of 4it gets paid again without selling againderived 2026-09-08accession 0000872589-26-000025
Sanofi collaboration revenue (most of which is attributable to our share of profits from the commercialization of Dupixent) represented 48% and 39% of our total revenues for the six months ended June 30, 2026 and 2025, respectively
The increase in our share of profits for the three and six months ended June 30, 2026, compared to the same periods in 2025, was driven by higher profits primarily associated with an increase in Dupixent net product sales
We co-commercialize Dupixent in the United States and in certain countries outside the United States
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedfour sentences · whole, uncut
the claims it rests on
“Sanofi collaboration revenue (most of which is attributable to our share of profits from the commercialization of Dupixent) represented 48% and 39% of our total revenues for the six months ended June 30, 2026 and 2025, respectively”
“The increase in our share of profits for the three and six months ended June 30, 2026, compared to the same periods in 2025, was driven by higher profits primarily associated with an increase in Dupixent net product sales”
“We co-commercialize Dupixent in the United States and in certain countries outside the United States”
what it was checked against
Dupixent revenue concentration percentages
“For the six months ended June 30, 2026 and 2025, Sanofi collaboration revenue (most of which is attributable to our share of profits from the commercialization of Dupixent) represented 48% and 39% of our total revenues, respectively.”